
Alcon and Lensar Agree to Terminate Merger Agreement
Published on March 18, 2026
GENEVA and ORLANDO, Fla.—Global eyecare leader Alcon (SIX/NYSE: ALC), announced that it has entered into an agreement with Lensar, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, to terminate the companies’ previously announced merger agreement. Alcon had originally agreed to acquire Lensar, Inc. for up to $430 million in March of 2025. The decision to end the merger agreement between the companies was driven by opposition from the Federal Trade Commission (FTC), the companies stated, which had signaled its intention to block the proposed acquisition.
